Sign in →

Test ID VCOV2 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgG Antibody, Serum


Advisory Information


Molecular testing is the recommended for diagnosis of coronavirus disease 2019 (COVID-19) in symptomatic patients. For more information see:

-COVID / Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Detection, Varies

-SARS2 / Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA, Varies

For the most up-to-date COVID-19 epidemiology and testing recommendations, visit

https://www.cdc.gov/coronavirus/2019-ncov/index.html



Necessary Information


Date of collection is required.



Specimen Required


Patient Preparation: For 24 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.

Supplies: Aliquot Tube, 5 mL (T465)

Collection Container/Tube: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 2 mL

Collection Instructions: 

1. Centrifuge blood collection tube per collection tube manufacturer's instructions (eg, centrifuge and aliquot within 2 hours of collection for BD Vacutainer tubes).

2. Aliquot serum into plastic vial.


Useful For

Detection of IgG-class antibodies against severe acute respiratory syndrome coronavirus 2, agent of coronavirus disease 2019 (COVID-19)

Method Name

Chemiluminescence Immunoassay

Reporting Name

SARS-CoV-2 IgG Ab, S

Specimen Type

Serum

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  30 days
  Ambient  24 hours

Clinical Information

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Like other coronaviruses that infect humans, SARS-CoV-2 can cause both upper and lower respiratory tract infection. Symptoms can range from mild (ie, the common cold) to severe (ie, pneumonia) in both healthy and immunocompromised patients. SARS-CoV-2 transmission occurs primarily via respiratory droplets. During the early stages of COVID-19, symptoms maybe nonspecific and resemble other common respiratory tract infections, such as influenza.

 

The incubation period for COVID-19 ranges from 5 to 7 days. Typically, immunocompetent individuals with COVID-19 develop detectable IgG-class antibodies against SARS-CoV-2 approximately 8 to 11 days following onset of symptoms. Patients tested prior to this time may be negative for SARS-CoV-2 IgG antibodies.

Reference Values

Negative

Interpretation

Negative: No IgG antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detected. Negative results may occur in serum collected too soon following infection, in immunosuppressed patients, or in some individuals with prior mild illness. Follow-up testing with a molecular test is recommended in symptomatic patients. This test should not be used to exclude active/recent coronavirus disease 2019 (COVID-19).

 

Positive: SARS-CoV-2 IgG antibodies detected. Results suggest recent or prior infection with SARS-CoV-2. Correlation with epidemiologic risk factors and other clinical and laboratory findings is recommended. Serologic results should not be used to diagnose recent SARS-CoV-2 infection. Protective immunity cannot be inferred based on these results alone. Infrequently, false-positive results may be due to prior infection with other human coronaviruses.

Clinical Reference

1. Okba N, Muller MA, Li W, et al: Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis. 2020 Apr 8;26(7). doi: 10.3201/eid2607.200841

2. Amanat F, Stadlbauer D, Strohmeier S, et al: A serologic assay to detect SARS-CoV-2 seroconversion in humans. medRxiv 2020.03.17.20037713. doi: 10.1101/2020.03.17.20037713. Available at www.medrxiv.org/content/10.1101/2020.03.17.20037713v2

3. Liu L, Liu W, Wang S, Zheng S: A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. medRxiv 2020.03.06.20031856. doi: 10.1101/2020.03.06.20031856 Available at www.medrxiv.org/content/10.1101/2020.03.06.20031856v1

4. Zhang W, Du RH, Li B, et al: Molecular and serologic investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020 Feb 17;9(1):386-389.  doi: 10.1080/22221751.2020.1729071

Day(s) and Time(s) Performed

Monday through Sunday; Varies

Analytic Time

Same day/1 day

Test Classification

This test has received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86769

LOINC Code Information

Test ID Test Order Name Order LOINC Value
VCOV2 SARS-CoV-2 IgG Ab, S 94563-4

 

Result ID Test Result Name Result LOINC Value
VSARS SARS-CoV-2 IgG Ab, S 94563-4

Forms

If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.